Main > ONCOLOGY (**) > Leukemia>Myeloid>Acute>FLT3+ *** > Treatment > CH. N. Midostaurin



CH. N. Midostaurin's subsections
(*) EU Approval Date: 2017. 09.20.
(*) USA Approval Date: 2017. 04.28.
Companion Diagnostic Test>
Company
FLT: FMS-Like Tyrosine kinase 3>
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 2
Patent>UpDate: 2018. 10.09.
TradeMark
TradeMark Web-Site
UpDate: 2017. 09.21.

CH. N. Midostaurin's products
This section has no products